Robert C. Goeltz II is CFO at Arcus Biosciences, Inc. (RCUS). They have made 5 open-market trades across 2 companies since 2017, most recently 2026-05-11.
CIK 0001653881
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $108K since 2020, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RCUS | 84,161 | $1.9M |
| CTMX | 32,756 | $75K |
| UBX | 161,027 | $32K |
| Total | $2.0M |
Shares reported on the most recent Form 4, priced at the 2026-05-12 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RCUS | SELL · 10b5-1 | 2026-05-11 | 2026-05-12 | $25.63 | $199K | -6.6% | -6.9% | +14.4% |
| RCUS | SELL · 10b5-1 | 2025-12-31 | 2026-01-02 | $23.38 | $153K | +5.4% | -7.1% | -1.5% |
| RCUS | SELL | 2025-12-16 | 2025-12-18 | $22.01 | $557K | +8.4% | -0.1% | +1.0% |
| RCUS | SELL · 10b5-1 | 2025-11-26 | 2025-11-26 | $25.00 | $125K | -2.9% | -10.5% | -21.8% |
| RCUS | SELL · 10b5-1 | 2025-10-28 | 2025-10-29 | $20.00 | $100K | -2.7% | +30.5% | +14.9% |
| RCUS | SELL · 10b5-1 | 2024-12-31 | 2025-01-03 | $15.00 | $54K | -6.1% | -12.2% | -52.3% |
| RCUS | SELL · 10b5-1 | 2024-01-02 | 2024-01-04 | $20.00 | $40K | -8.7% | -18.2% | -4.9% |
| RCUS | SELL · 10b5-1 | 2023-06-07 | 2023-06-09 | $20.04 | $162K | -8.5% | +3.8% | +1.0% |
| RCUS | SELL | 2022-12-16 | 2022-12-16 | $30.71 | $139K | -33.9% | -33.7% | -44.7% |
| RCUS | SELL | 2021-12-16 | 2021-12-20 | $40.12 | $44K | -1.3% | -18.3% | -15.6% |
| RCUS | BUY | 2020-09-09 | 2020-09-09 | $21.57 | $108K | -18.4% | -16.4% | +27.5% |
| CTMX | SELL | 2017-03-20 | 2017-03-21 | $19.81 | $426K | -5.7% | -11.9% | -22.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.